This trial is looking at whether having hormone therapy for 2 weeks before and 2 weeks after surgery helps postmenopausal women with breast cancer. The trial is supported by Cancer Research UK.
The first treatment for early breast cancer is usually surgery. After surgery, women who have hormone receptor positive breast cancer will have hormone therapy as part of their treatment. Most women have hormone therapy for at least 5 years. This helps to reduce the risk of breast cancer coming back.
Drugs called aromatase inhibitors are a type of hormone therapy for women who have gone through the menopause. In this trial, doctors want to find out if having an aromatase inhibitor for 2 weeks before and after surgery, as well as standard hormone therapy, helps reduce the risk of breast cancer coming back even more.
The researchers will also look at testing the cancer cells to see if there are any changes after a short course of hormone therapy. In the future, this may help doctors to work out which treatment is best for each individual patient. The aims of the trial are to
- See if 4 weeks of an aromatase inhibitor at the time of surgery helps to reduce the risk of early breast cancer coming back
- Find out if testing the cancer cells after 2 weeks of hormone therapy can help to predict how well a woman will respond to treatment
For more information about this trial go to :
A snapsot video of the the 2016 course is now available on YouTube VOICE2016
At the BACR/ECMC conference in July Maggie Wilcox and Mairead Mackenzie were persuaded to speak to the camera. Maggie gave a background to ICPV and our aims and objectives. While Mairead focused on her specific interests and activities. To view follow the links below.
July 2016 Conferences
ICPV members were busy this week with two conferences. The BACR/ECMC Joint Meeting on Therapeutic Interventions for Cancer Prevention was held in Bristol July18-19. The UK Breast Cancer Research Symposium was held in London from July 22-23. Click here for more information.
UK Therapeutic Cancer Prevention Network (UKTCPN)
An update from this new group was presented to the ECMC Annual Network Meeting in May 2016. Click here to download and read.
The ICPV Science for Advocates Course will be hosted by Warwick CTU from 19th - 23rd September. See the VOICE pages for more information.
The Voice, Winter 2015-2016
The latest ICPV newsletter is now available. It has reviews of members activities, meeting attended and papers published. Go to the ICPV Publications page to download.
Call for immediate change to European Paediatric Medicine Regulation to save more lives of children and teens with cancer.
A few basic changes to European Law could speed up access to newer, kinder and potentially better drugs for more children and teenagers with cancer. Click to Sign the petition
Two years on from the start pioneering TRACERx lung cancer study. Click here For the latest news and patient views on this study.
NCRI Conference 2015, Liverpool
ICPV members will be joining cancer researchers from 1-4 Nov, 2015. Click here for more information.
ICPV Summer School 2015
Qualitative Research Training Course at Warwick. Click here for a review of the session.
NCIN, Belfast, June 2015
Several ICPV members attended and spoke at this years conference. Click here for more.
AACR Conference, Philadelphia, April 2015
ICPV Member Pat Fairbrother joined US advocates at this year's conference. Read her review of the event here.
Cancer Drugs Fund
Today (19 Jan 2015) The Telegraph has published a letter from ICPV & fourteen other charities on the current CDF situation. Go to our Facebook or Twitter page for Telelgraph weblink or click below for the letter.